A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer

Overview

Información sobre este estudio

The purpose of this study is to assess late > grade 3 GI and/or GU toxicity of interest with the hypofractionated regimen with proton beam therapy or IMRT (late defined as 3 to 24 months after protocol RT).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Male participant.
  • Age ≥ 18 years old.
  • Histological confirmation of prostate adenocarcinoma.
  • Recurrent prostate cancer after prior receipt of primary radiotherapy to the prostate (can also include treatment of SVs and LNs) or salvage RT to the prostate fossa (can also include prior pelvic RT).
  • Oligometastatic extent of disease.
  • Recurrent disease involving lymph nodes as diagnosed with choline  PET/CT or other advanced PET imaging (PSMA or flucyclovine).
  • Limited to pelvic and/or retroperitoneal/para-aortic lymph nodes.
  • Zubrod performance score (PS) ≤ 1.
  • Signed informed consent.

Exclusion Criteria:

  • Bone or visceral metastases present.
  • Lymph node metastases beyond the pelvis and/or retroperitoneum.
  • Contraindications to RT (e.g., uncontrolled inflammatory bowel disease).
  • Contraindications to androgen suppression.
  • Concurrent antineoplastic agents (chemotherapy).
  • Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer.
  • Inability to start the protocol treatment within 6 months after study enrollment.
  • Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Brian Davis, M.D., Ph.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20472608

Mayo Clinic Footer